[
    {
        "file_name": "artaratherapeuticsinc_20200110_8-k_ex-10.5_11943350_ex-10.5_license agreement.pdf",
        "perturbation": [
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "3.2 Approval Milestone based on Data Value: Within forty-five (45) days of an approval of the TARA-002 BLA by the FDA, ArTara will pay a one-time approval milestone to University pursuant to the usefulness of the Program Data in TARA-002’s BLA filing, as set forth below:\n\nOfficial Feedback from FDA regarding the Program Data\nMilestone\n[…***…]\n$[…***…]\n[…***…]\n$[…***…]\n[…***…]\n$[…***…]\n[…***…]\n$[…***…]",
                "changed_text": "3.2 Approval Milestone based on Data Value: Within thirty (30) days of an approval of the TARA-002 BLA by the FDA, ArTara will pay a one-time approval milestone to University pursuant to the usefulness of the Program Data in TARA-002’s BLA filing, as set forth below:\n\nOfficial Feedback from FDA regarding the Program Data\nMilestone\n[…***…]\n$[…***…]\n[…***…]\n$[…***…]\n[…***…]\n$[…***…]\n[…***…]\n$[…***…]",
                "explanation": "Changing the payment deadline from forty-five (45) days to thirty (30) days after BLA approval creates a direct contradiction. This inconsistency creates ambiguity regarding when the milestone payment is actually due, leading to potential disputes and uncertainty in enforcement.",
                "location": "Section 3.2"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "3.5 Sales Milestone Payments. In the event that Annual Net Sales, as detailed in Section 3.3, surpass certain thresholds, ArTara will make the\nfollowing payments no later than […***…] following the close of the calendar quarter in which each milestone is reached as set forth below:\nAnnual Net Sales of Product for the \nIndication Exceeds\nMilestone Payment\n$25,000,000\n$62,500\n$50,000,000\n$62,500\n$100,000,000\n$125,000",
                "changed_text": "3.5 Sales Milestone Payments. In the event that Annual Net Sales, as detailed in Section 3.3, surpass certain thresholds, ArTara will make the\nfollowing payments no later than ninety (90) days following the close of the calendar quarter in which each milestone is reached as set forth below:\nAnnual Net Sales of Product for the \nIndication Exceeds\nMilestone Payment\n$25,000,000\n$62,500\n$50,000,000\n$62,500\n$100,000,000\n$125,000",
                "explanation": "Replacing the redacted timeframe ([...***...]) with 'ninety (90) days' creates an inconsistency if another section specifies a different timeframe or requires faster payments. This contradiction leads to uncertainty about the actual payment deadline and potential disputes. Depending on how the blank was intended, there can be an enforcement disagreement.",
                "location": "Section 3.5"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "8.1 Term. This Agreement may be terminated by ArTara upon thirty (30) days prior written notice to University.",
                "changed_text": "8.1 Term. This Agreement may be terminated by ArTara upon sixty (60) days prior written notice to University.",
                "explanation": "Changing the termination notice period from thirty (30) days to sixty (60) days creates a conflict. This inconsistency makes it unclear what the actual required notice period is for termination, potentially causing legal disputes and impacting business planning.",
                "location": "Section 8.1"
            }
        ]
    }
]